Author

Chinyu Su 1

1 Pfizer Inc,Collegeville,United States

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi, Christina Ha, Michael Chiorean, Nervin Lawendy, Rajiv Mundayat, Leonardo Salese, John C. Woolcott, Chinyu Su, Iris Dotan

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, Geert R. D'Haens, William J. Sandborn, Julian Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, nicole kulisek, Irene Modesto, Siew C. Ng, Joana Torres

BASELINE ALBUMIN LEVEL IS NOT A SIGNIFICANT PREDICTOR OF TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF MULTIVARIATE EXPOSURE-RESPONSE ANALYSIS

Gary R. Lichtenstein, Andrew Tinsley, Xavier Roblin, Tadakazu Hisamatsu, Camille Vong, Shinichi Tsuchiwata, Konstantinos Tsilkos, Haiying Zhang, Arnab Mukherjee, Chinyu Su, David T. Rubin

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Daniel C. Baumgart, Chinyu Su, Kenneth Kwok, Jami A. Kinnucan, Xiang Guo, Susan B. Connelly, Edward V. Loftus Jr., Krisztina B. Gecse, Alessandro Armuzzi

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

Edward V Loftus Jr., Alessandro Armuzzi, Daniel C. Baumgart, Jeffrey R Curtis, Jami A. Kinnucan, Nana Koram, Leonardo Salese, Chinyu Su, Kenneth Kwok, John Woolcott

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés, Jean-Frederic Colombel, Severine Vermeire, Marla C. Dubinsky, Ala I. Sharara, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Edward V. Loftus Jr.

Faecal calprotectin levels, C-reactive protein levels and partial Mayo score as early predictors of clinical and endoscopic outcomes in adult patients with moderately to severely active ulcerative colitis treated with tofacitinib in a Phase 2 study

Marla C. Dubinsky, David P. Hudesman, nicole kulisek, Leonardo Salese, Jerome Paulissen, Chinyu Su, Fernando Magro

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Kevin L. Winthrop, Gil Y. Melmed, Severine Vermeire, Nervin Lawendy, Rajiv Mundayat, nicole kulisek, Chinyu Su

Item 1 - 10 / 37
1
2 3 4